This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Diabetes Heart Failure Obesity 
Cardiovascular Diabetology
SEPTEMBER 15, 2024
Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. During the 4.22-year
98 
Cardiovascular Diabetology
FEBRUARY 11, 2024
Heart failure (HF) is increasing at an alarming rate, primary due to the rising in aging, obesity and diabetes. Notably, individuals with type 1 diabetes (T1D) face a significantly elevated risk of HF, leading.
111 
Science Daily - Heart Disease
NOVEMBER 20, 2024
Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with obesity and heart failure with preserved pump function, new research reveals.
111 
DAIC
MARCH 26, 2025
Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
American College of Cardiology
APRIL 6, 2024
The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).
Med Page Today
APRIL 7, 2024
(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.
Science Daily - Heart Disease
JUNE 23, 2024
Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men.
101 
American College of Cardiology
JANUARY 15, 2025
Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF. In this interview, Drs.
American College of Cardiology
JANUARY 8, 2024
Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.
71 
Open Heart
MAY 23, 2024
Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. It is not known whether heart failure increases the risk of pre-eclampsia. This study examines whether pregestational heart failure increases the risk of pre-eclampsia.
HeartRhythm
APRIL 30, 2024
We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D). However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients.
American College of Cardiology
APRIL 10, 2024
What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?
Cardiovascular Diabetology
FEBRUARY 16, 2025
Obesity is common in the heart failure (HF) population and is regarded as an important risk factor for developing HF. Greater skeletal muscle mass has shown to be the underlying protective factor against cardi.
American College of Cardiology
JUNE 24, 2024
Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)
Cardiovascular Diabetology
MARCH 21, 2025
Heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly prevalent worldwide due to aging and comorbidities. Epicardial adipose tissue (EAT), favored by diabetes and obesity, was shown to co.
European Journal of Heart Failure
OCTOBER 9, 2024
Cardiovascular outcomes with exenatide in type 2 diabetes (T2D) according to left ventricular ejection fraction (LVEF): the EXSCEL trial. CI, confidence interval; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HHF, hospitalization for heart failure; HR, hazard ratio; NYHA, New York Heart Association.
75 
Cardiovascular Diabetology
MARCH 25, 2025
Heart failure (HF) is increasingly recognized as a heterogeneous cardiometabolic disorder, often in the context of overweight/obesity independently from diabetes. Sodium-glucose cotransporter-2 inhibitors (SGL.
The British Journal of Cardiology
OCTOBER 8, 2024
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering and weight-lowering agents used in the management of type 2 diabetes mellitus and obesity.
40 
Frontiers in Cardiovascular Medicine
DECEMBER 17, 2023
These conditions have an increasing share in the health burden worldwide due to worsening endemic of hypertension, obesity, and diabetes. However, the same set of genes were significantly induced in the Trp53inp2-cKO hearts under both mechanical and metabolic stresses.
Cardiometabolic Health Congress
JULY 25, 2023
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
52 European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′. Overall, 60.9%
DAIC
JUNE 18, 2024
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 trillion by 2050, according to two American Heart Association ( AHA ) presidential advisories published June 4 in the AHA journal Circulation.
105 
MIBHS
MARCH 15, 2025
Studies show that repeated binge drinking can contribute to spikes in blood pressure, increasing the likelihood of stroke, heart attack, and heart failure. Heart Muscle Damage and Heart Failure The impact of drinking alcohol on the heart muscle is another critical area of concern.
Journal of the American Heart Association
DECEMBER 29, 2023
AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.
45 
Dr. Paddy Barrett
AUGUST 9, 2024
The 14 Factors Include: Hearing Loss High LDL cholesterol Less Education Traumatic Brain Injury Depression Social Isolation Hypertension Obesity Smoking Excess Alcohol Diabetes Physical Inactivity Air Pollution Visual Loss Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission When You Intervene Matters.
115 
CardiacWire
AUGUST 23, 2024
It looks like we might be able to add prediabetes and hypertension to the growing list of conditions that Eli Lilly’s “weight loss drug” tirzepatide is able to treat, after new analysis of the SURMOUNT-1 trial showed significant reductions in blood pressure and diabetes progression. mm Hg systolic and 4.2 of placebo-takers.
64 Stroke Journal
JANUARY 30, 2025
Background:Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown a reduction in major adverse cardiovascular events (MACE) among patients with type 2 diabetes mellitus (T2DM). Similarly, the risk of serious adverse events such as cerebrovascular accident (OR, 0.75(95%CI: 1.00),P=0.05), hemorrhagic stroke (OR, 0.82(95%CI:
AMS Cardiology
NOVEMBER 21, 2024
While the holidays themselves can’t cause a heart attack , certain things people do during the hectic, festive season may stress their heart health more than they realize. Plus, these stressors can increase the risk of heart attack, stroke or retention of extra fluid and heart failure , explains Dr. Tarditi.
Circulation: Heart Failure
JANUARY 28, 2025
Circulation: Heart Failure, Ahead of Print. BACKGROUND:The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. compared with single condition exposure 5.21.3% (obesity), 6.73.5% (hypertension), and 9.01.1% (diabetes;P<0.001). ms (36.4106.4;P=0.028)
Circulation
JUNE 4, 2024
Diabetes (16.3% to 26.8%) and obesity (43.1% to 9.2%), heart failure (2.7% We projected through 2050, overall and by age and race and ethnicity, accounting for changes in disease prevalence and demographics.RESULTS:We estimate that among adults, prevalence of hypertension will increase from 51.2% in 2020 to 61.0%
81 
American College of Cardiology
FEBRUARY 12, 2024
What is the value of the new American Heart Association’s (AHA’s) PREVENT equation(s) for primary prevention that use routinely available clinical variables including obesity, diabetes, kidney disease, and social risk for predicting 10- and 30-year absolute risk of cardiovascular disease (CVD) including each atherosclerotic CVD (ASCVD) and heart (..)
CardiacWire
AUGUST 2, 2024
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity. vs. +15 KCCQ-CSS points).
59 
Frontiers in Cardiovascular Medicine
FEBRUARY 4, 2024
Notably, MAM exhibits various regulatory effects to maintain cellular balance in several cardiac diseases conditions, such as obesity, diabetes mellitus, and cardiotoxicity. Cardiac diseases caused by any reason can lead to changes in myocardial structure and function, significantly impacting human health.
69 HeartRhythm
MARCH 12, 2024
Diabetes mellitus (DM) is a public health problem that continues to grow worldwide. 2 As noted elsewhere,3 DM and AF affect a population that shares concomitant conditions such as obesity, hypertension and even heart failure (HF). of the population.1 of the population.1 Further, DM is a major risk for AF.
Circulation: Heart Failure
MARCH 8, 2024
Circulation: Heart Failure, Ahead of Print. Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. Results:Median age was 73 (25th–75th percentile 67–81) years, 53.2% were female, 25.6% were Black, 12.8% were Chinese, and 40.0% were White.
All About Cardiovascular System and Disorders
FEBRUARY 27, 2024
They have a greater prevalence of obesity, dyslipidemia, metabolic syndrome and diabetes mellitus. Higher risk of myocardial infarction, heart failure and atrial fibrillation was noted in spinal cord injury survivors compared to controls. Survivors with severe disability had the highest risk. Am J Phys Med Rehabil.
DAIC
SEPTEMBER 11, 2024
A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. Earlier projections had estimated that 3.3 million U.S. The study appears Sept. The study appears Sept.
Nature Reviews - Cardiology
MAY 27, 2024
Nature Reviews Cardiology, Published online: 28 May 2024; doi:10.1038/s41569-024-01042-w In patients with type 2 diabetes mellitus and obesity, bariatric metabolic surgery is associated with a lower risk of the incidence of first-ever congestive heart failure than treatment with glucagon-like peptide 1 receptor agonists, according to a new study.
43 
American College of Cardiology
AUGUST 30, 2024
Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19-related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC.
40 
Journal of Cardiovascular Pharmacology
JUNE 24, 2024
Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic medications which have proved capable of providing breakthrough cardiovascular benefits in a variety of clinical scenarios, including patients with heart failure or obesity, irrespective of diabetic status.
DAIC
FEBRUARY 29, 2024
12:15 p.m.
103 
Frontiers in Cardiovascular Medicine
JULY 22, 2024
years to monitor MACEs (cardiovascular death, cardiogenic shock, recurrent myocardial infarction, and heart failure).ResultsWe Hypertension (42.4%), smoking (34.3%), type 2 diabetes mellitus (31.2%), obesity (22.92%), and dyslipidemia (21.4%) were highly prevalent. Patients were followed up for 4.5
CardiacWire
OCTOBER 27, 2024
It’s well known that heart disease is the U.S.’s Heart Disease in 2050 – The AHA warned of massive heart disease increases by 2050, spanning CVD (+60%), diabetes (+100%), obesity (+70%), hypertension (+44%), heart failure (+66%), and stroke (+100%). trillion, representing 4.6% of US GDP.
59 Journal of the American Heart Association
FEBRUARY 26, 2025
Multimorbidity was defined as 2 comorbidities (heart failure, hypertension, diabetes, coronary heart disease, kidney dysfunction, moderate or severe mitral valve regurgitation, or obesity). AF symptom severity was assessed via the University of Toronto AF Severity Scale questionnaire.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content